001 and ABCA1-dependent: 7.9±1.9 vs. 12.0±2.0, p<0.0005). Similarly, NASH patients had

significantly lower PON1 activity (0.89±0.06 vs. 1.02±0.07, p<0.005). Serum triglyceride and glucose levels were negatively correlated with cholesterol efflux and PON1 activity. Insulin resistance (HOMA) negatively correlated with cholesterol efflux but not with PON1 activity. Hepatic oxidation in patients with NASH correlated with both cholesterol efflux and PON1 activity. Conclusions. HDL function measured using cholesterol efflux and PON1 activity are inversely correlated with CVD risk. HDL dysfunction may contribute to CVD related mortality in NASH. Disclosures: The following people have nothing to disclose: Arthur J. McCullough, Jaividhya Dasarathy, Ling Li, Gregory Brubaker, Belinda Willard, Srinivasan Dasarathy, Jonathan D. Smith, Takhar Kasumov Background: Non-alcoholic fatty liver disease (NAFLD) continues to increase in incidence. Currently, there is no standardized Alectinib in vivo regimen for treatment of NAFLD. Purpose: We performed a meta-analysis of randomized placebo controlled

trials (RCTs) that evaluated thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone, as well as metformin and vitamin E in adult patients with NAFLD in order to quantify the treatment response. Outcome measures were improvement in liver histology and biochemical and anthropometric measures. Methods: For discrete variables, Odds ratio and 95% confidence intervals were calculated using a random-effects model. For continuous variables weighted averages were calculated.

Study heterogeneity and publication bias were assessed. Four trials of TZDs, four this website of metformin and three with Vitamin E met inclusion criteria. Results: The liver histology score including steatosis (OR 3.40, 95% CI 2.21 to 5.25), ballooning (OR 1.67, 95% CI 1.04 to 上海皓元医药股份有限公司 2.68) and lobular inflammation (OR 2.58, 95% CI 1.68 to 3.97) all showed a greater proportion of improvement with TZD use as compared to placebo. The hepatic fibrosis score (OR 1.57, 95% CI 0.98 to 2.50) did not demonstrate significant improvement with TZDs. Weighted mean difference in ALT (−19.43, P=0.0007) and Hemoglobin A1c (HbA1C) (−0.43, P=0.0006) demonstrated significant improvement with TZD use. Weighted mean difference in body weight with TZD (P=0.20) and BMI (P=0.55) showed a non-significant increase compared to placebo. With met-formin, weighted liver histologic scores for steatosis (mean difference 0.15, P=0.27), ballooning (-0.05, P=0.43), lobular inflammation (0.07, P=0.12) and fibrosis (−0.198, P=0.15) did not demonstrate significant change compared to placebo. Weighted mean difference in fasting blood sugar (−8.45 mg/ dl, P<0.0001) demonstrated significant improvement with met-formin use. Weighted mean difference in ALT (P=0.25), body weight (P=0.56), and BMI (P=0.74) did not show significant change compared to placebo. With Vitamin E, weighted liver histologic scores for steatosis (−0.71, 95% CI −0.97 to −0.47, P<0.